IL1RL2 and neoplasm: Collectively this data indicates that IL-36 signalling is capable of inducing a pro-tumorigenic phenotype in IL-36R-expressing colon cancer cells, and thus should be considered carefully given the emerging data demonstrating an anti-tumorigenic function for IL-36R agonists within the TME through augmentation of the anti-tumour immune response.